Helsinn Healthcare Sa

Roche Palo Alto LLC

Other

Roberta Cannella

Daniele Bonadeo

Thomas R Malefyt

Andrew R Miksztal

Kathleen M Lee

Giorgio Calderari

Alessio Venturini

Fabio Trento

Sergio Cantoreggi

Alberto Macciocchi

Giorgia Rossi

Valentino J Stella

Peter Manini

Claudio Pietra

Claudio Giuliano

Luca Fadini

Emanuela Lovati

Riccardo Braglia

Enrico Braglia

Carmine Panuccio

Ricardo Braglia

Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.

Physiologically balanced injectable formulations of fosnetupitant

Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.

Compositions and methods for treating centrally mediated nausea and vomiting

Fosnetupitant chloride hydrochloride having improved stability, characterized by the following chemical structure: 

Fosnetupitant chloride hydrochloride having improved stability

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK) receptor. The compounds have the general formula (I): 

Substituted piperaziniums for the treatment of emesis

Disclosed is a solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium (fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone and its application in methods for preventing acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy.

Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator

The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.

Liquid pharmaceutical formulations of palonosetron

Compounds and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK) receptor, based on 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)3yridine-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium and pharmaceutically acceptable salts thereof.

4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator

Growing community of inventors

Varese, Italy

Roberta Cannella